THE POWER OF HMB IN SUPPORTING PATIENTS’ MUSCLE MAINTENANCE AND RECOVERY

HMB Header

Muscle is a dynamic tissue. It is continually in a cycle of synthesis and breakdown (or degradation), building new tissue and breaking down old.1-2 To maintain muscle mass, the goal is to ensure that muscle breakdown is not happening faster than muscle synthesis.2

But as we age, this can become more difficult, as muscle loss naturally accelerates due to muscle breakdown increasing and muscle synthesis reducing. This problem is compounded by hospitalisation, mobility limitations or catabolic illness. For example, in patients who are frail, have cancer or COPD.3

Amino acid formula icon

THE ROLE OF HMB IN MUSCLE MAINTENANCE AND REPAIR

We know that protein plays a significant role in muscle health. But where breakdown is happening faster than synthesis, consuming dietary protein may not be enough to restore the balance.3

This is where HMB comes in. It has three mechanisms of action. It supports muscle synthesis, whilst uniquely protecting muscle from breakdown. It also helps to stabilise muscle cell membranes, thereby improving the repair of damaged muscle cells.***,°,>,|,4-7

Symptoms icon

HMB HAS BEEN CLINICALLY PROVEN TO

FIND OUT MORE ABOUT THE IMPORTANT ROLE HMB PLAYS IN MUSCLE MAINTENANCE.

Review icon

THE BENEFITS OF ONS CONTAINING HMB ARE SUPPORTED BY A WEALTH OF CLINICAL EVIDENCE

Specialised ONS containing HMB have been proven to have a positive effect on patients with long-term health conditions.

Health benefits icon

CANCER
ONS containing HMB is proven to preserve muscle mass and function in cancer patients and can also positively impact hospitalisation outcomes, cancer-related toxicity and survival rates.9♢♢

Health benefits icon

COPD
ONS containing HMB has been shown to benefit muscle mass and strength in COPD patients and has been proven to reduce the risk of death by 71% in malnourished COPD patients**10

Health benefits icon

FRAILTY
ONS containing HMB has been shown to benefit mobility, accelerate wound healing and increase muscle strength in patients undergoing surgery for hip fracture§§,\,◆,♢,11

Nutrition Science icon THE POWER OF ABBOTT’S ONS WITH A UNIQUE BLEND CONTAINING HMB

Abbott’s unique blend of high protein, HMB and vitamin D is clinically proven to help reduce muscle loss and support strength and recovery
from illness, injury and surgery.12-14

HIGH PROTEIN

Adequate protein intake is essential to help minimise declines in strength and function5

HMB
 

HMB is a metabolite of leucine, a branched-chain essential amino acid exclusively obtained from dietary sources15

VITAMIN D

Acts directly on muscle to promote its function through specific vitamin D receptors found on muscle cells16

More than 18 clinical studies have shown that Abbott’s ONS with a unique blend, including HMB, can improve patient outcomes
in more ways than one:

  • Preserves muscle mass*,†,‡,§,||,¶,~,17-23
  • Increases parameters of strength**,††,‡‡,§§,¶,¶¶,~,11,22-27
  • Improves physical function‡,#,§§,¶,11,20,22,28
  • Improves mobility post-surgery§§,11
  • Accelerates wound healing§§,11
  • Improves quality of life#,¶,~,22-23,28
  • Reduces risk of mortality**, ##,25,29

Online resources icon

DISCOVER MORE ABOUT HMB

PODCAST: THE IMPORTANCE OF MUSCLE MASS AND HMB DURING ILLNESS

In this 25-minute podcast episode, Dr Suzette Pereira discusses how muscle mass can impact the health status and outcomes of severely ill patients, and how ingredients like HMB can support recovery.

INFOGRAPHIC: THE ROLE OF LEUCINE AND HMB INFOGRAPHIC

This infographic highlights the role of leucine and its metabolite HMB in supporting muscle health in aging and illness.

Footnotes:

COPD - Chronic obstructive pulmonary disease.
***HMB (Beta-hydroxy-beta-methylbutyrate) is an active metabolite of leucine, among the constituent elements of proteins, naturally found in some foods, but in small quantities.
°Studied in healthy young males, over a period of 2.5 hours after receiving HMB supplementation.
>Compared to baseline at post-absorptive state.
|In a RCT including 19 healthy adults aged ≥60 years confined to bed rest for 10 days. CaHMB (3 g daily) prevented the decline in total LBM over bed rest (-0.17 ± 0.19 kg; p =0.23) in treated group versus control group (-2.05±0.66 kg; p =0.02). \Postoperative nutrition provided 1900 kcal and 76 g protein a day.
♢Study design: A randomised control trial to investigating the effects of a specialised ONS on 75 older malnourished women (≥65 years) who underwent surgery for hip fracture vs standard post operative nutrition. Patients were mobile and ambulatory before the fracture.
◆Patients in the intervention group (n=32) + specialised ONS§. Patients in the control group (n=30) received standard post-operative nutrition (1900 kcal, 76 g protein per day) alone.
*In older community living adults (>60 years) receiving outpatient care with or at risk of malnutrition.
†In 283 adult patients with or at risk of malnutrition under standard of care, 63% being cancer patients.
‡In 62 community-dwelling pre-frail older people taking a specialised ONS vs nutritional counselling over 12 weeks.
§In 61 patients undergoing radical cystectomy receiving either a specialised ONS or vitamin/mineral supplement twice daily for 8 weeks.
||In 92 patients aged 65 and over with hip fractures admitted to a rehabilitation facility, either receiving a standard diet plus 2 bottles of the study product or a standard diet only. Standard diet provided 1500 kcal, 87.4 g protein a day.
¶An open-label study of elderly (n=35) patients with recent weight loss (>5% during previous 3 months) showed that 12 weeks supplementation of experimental product twice daily increased dietery intake, biochemical variables, and quality of life compared to baseline.
~As shown in a randomised controlled trial in which normally nourished patients with non-cystic fibrosis bronchectasis received pulmonary rehabilitation plus a specialised ONS or pulmonary rehabilitation only for 12 weeks. In the intervention group, mean and maximum handgrip dynamometry, physical functioning domain of QOL-B-V3.0 and other outcomes were significantly increased from baseline at 12 weeks and 24 weeks and fat free mass at 12 weeks.
**As shown in a randomised control trial to investigate the effects of the intervention ONS on malnourished, cardiopulmonary patients (≥65 years) vs placebo. The intervention ONS decreased mortality at 90 days post-discharge, however the study did not observe a significant effect for the primary composite endpoint of non-elective readmission or death. This post-hoc, sub-group analysis from the NOURISH study cohort comprised 214 COPD patients.
††Strength was measured by handgrip strength in a post hoc analysis of over 600 malnourished people with heart or lung diseases, age 65 or older. Study product was consumed twice a day for 30 days, as compared to standard of care.
‡‡In 330 older adults with malnutrition and sarcopenia. Muscle quality was calculated as leg strength expressed relative to the muscle mass.
§§As shown in a randomised control trial to investigate the effects of a specialised ONS on older women (≥65 years) who underwent surgery for hip fracture vs. standard post-operative nutrition. Post-operative nutrition provided 1900 kcal and 76 g protein a day. Muscle function was measured by handgrip strength. Mobilisation status was assessed on post-operative days 15 and 30.
¶¶In 65 healthy older female patients who regularly attended a fitness programme.
#In a single arm open-label study of 148 patients aged 80±8.3 years with or at risk of malnutrition who consumed experimental product twice daily for 12 weeks as compared to baseline.
##As shown in a randomised control trial to investigate the effects of the intervention ONS on malnourished, cardiopulmonary patients (≥65 years) vs placebo. The intervention ONS decreased mortality at 90 days post-discharge, however the study did not observe a significant effect for the primary composite endpoint of non-elective readmission or death.
~~In 102 nursing home residents ≥75 years old randomised into an intervention group (the intervention consisted of a combinationof sit-to-stand test 4 times/day and 2 bottles of a high protein low volume ONS) or a control group for 12 weeks.
♢♢A systematic review of 15 studies (n=943) published up to December 2021 including adults patients with various cancer types and treatments consuming HMB-ONS for 10 days-6 months

References:

1.Carbone JW &Pasiakos SM. Nutrients 2019;11(5):1136.
2. Tipton KD et al. Sports Med 2018;48(1):53-64.
3. Argilés JM et al. J Am Med Dir Assoc 2016;17(9):789-96.
4. Wilkinson DJ et al. J Physiol 2013;591:2911-23.
5. Deutz NE et al. Clin Nutr 2014;33(6):929-936.
6. Nissen SL & Abumrad NN. J Nutr Biochem 1997;8:300-311.
7. Deutz NEP et al. Clin Nutr 2013;32:704-712.
8. Engelen MPKJ & Deutz NEP. Curr Opin Clin Nutr Metab Care 2018;21(3):207-213.
9. Prado CM et al. J Cachexia, Sarcopenia Muscle 2022;13:1623–1641.
10. Deutz NE et al. Clin Nutr 2020: doi: 10.1016/j.clnu.2020.08.031.
11. Ekinci O et al. Nutr Clin Pract 2016;31(6):829-835.
12. Wolfe RR Am J Clin Nutr 2006;84:475-482.
13. Ceglia L Curr Opin Clin Nutr Metab Care 2009;12(6):628-633.
14. Bear DE et al. Am J Clin Nutr 2019;109(4):1119-1132.
15. Wilson GJ et al. Nutr Metab 2008;5:1.
16. Wagatsuma A and Sakuma K. Biomed Res Int 2014;2014:121254.
17. Ritch CR et al. J Urol 2019;201(3):470 477.
18. Chavarro Carvajal DA et al. Clin Nutr ESPEN 2022;48:291-297.
19. Cornejo Pareja I et al. Nutrients 2021;13(12):4355.
20. Peng LN et al. J Nutr Health Aging 2021;25(6):767-773.
21. Malafarina V et al. Maturitas 2017;101:42-50.
22. De Luis DA et al. Nutr Hosp 2015;32(1):202 207.
23. Olveira G et al. Clin Nutr 2016;35(5):1015-1022.
24. Matheson EM et al. Clin Nutr 2021;40(3):844-849.
25. Deutz NE et al. Clin Nutr 2021;40(3):1388-1395.
26. Cramer JT et al. JAMDA 2016;17(11):1044-1055.
27. Berton L et al. PLoS One 2015;10(11):e0141757.
28. De Luis DA et al. Eur Geriatr Med 2018;9(6):809-817.
29. Deutz NE et al. Clin Nutr 2016;35(1):18-26.

UK-N/A-2300357 (V2) | February 2024
Order ID: #12345
Order Date: 01/05/2024
Product Product Flavour Product Quantity
Click here to add this page to your bookmarks.

This page has been added to your bookmark. To access your bookmark list, Click here

Loading...

SESSION TIMEOUT

Your session is about to expire in {min} minutes and you will be logged out. Do you wish to stay logged in?
UK-N/A-2400058 (V8) | October 2024

You have now gained access to ProConnect for a limited time. We will now verify your details before your account becomes fully active.

You are now able to freely access all resources and education during this visit to the ProConnect website. An email will be sent to you within 2 working days to activate your account which will complete your registration process.

UK-N/A-2400058 (V8) | October 2024

JOIN ABBOTT'S GROWING NETWORK OF HEALTHCARE PROFESSIONALS

Sign up to receive marketing and medical communications from Abbott

Fields marked with an asterisk (*) are mandatory.   

Please enter a valid first name Please enter a first name Please do not add space or special characters on the field
Please enter a valid last name Please enter a last name Please do not add space or special characters on the field
Please enter a valid contact number starting with +44 Please enter a contact number Please enter a valid contact number starting with +44
Please enter a valid email address Please enter an email address Please enter a valid email address
Please enter a valid email address Please confirm your email address Please enter a valid email address
Please enter a valid email address Please enter a valid email address
Please enter a valid email address Please enter a valid email address
 
Please select an area of specialty
Only Select a UK place of work. If unable to select/locate one, please fill in manually in Place of Work/Trust. Please enter a valid postcode using the correct format (see information icon above). Please enter a postcode Please enter a valid postcode using the correct format (see information icon above).
Please enter a place of work/trust Please enter a place of work/trust Please enter valid work / trust. Do not use special characters in this box.
Please enter valid address Please enter a street Please enter valid street. Do not use special characters in this box.
Please enter valid city Please enter a city Please enter valid city. Do not use special characters in this box.
Please enter valid county Please enter a county Please enter valid county. Do not use special characters in this box.
Password does not follow password guidelines Please enter a password Password must have at least 8 characters, 1 number, and 1 special character

Password Requirements

Password must match Please confirm your password

Abbott would like to use your personal data to send to you emails on scientific and educational information, invitations to events, surveys and other relevant communications from Abbott (the “Purpose”). Abbott will not sell or transfer your personal information. Unless you have expressly consented, Abbott will not use it for any other purpose other than the Purpose. To be removed from the Abbott mailing list, you may unsubscribe at any time by managing your preferences in the 'my account' section. Access Abbott's Privacy Policy to learn more about how your data is managed.

 
Please agree to the site's terms of use

Have an account? Login Here

Success or error message

Sorry there has been an error in your registration, please contact our customer service team email: abbott.customerservices@nhs.net
Sorry there has been an error in your registration, please contact our customer service team email: abbott.customerservices@nhs.net
You have registered for an account using abc@gmail.com, however you have not yet activated your account. Please check your inbox for an email from proconnect@abbott.com to activate your account
You might already have an account with ProConnect. abc@gmail.com. Please try and login.
You might already have an account with ProConnect, abc@gmail.com. Please try and login.
UK-N/A-2400058 (V8) | October 2024

Added to Bag

ENSURE PLUS

1 x 220 ml

Flavor: Apple

UK-N/A-2400058 (V8) | October 2024

1,5 kcal / ml

Nutrition Information

Energy
 UnitPer {ml-col-1} mlPer {ml-col-2} ml
 
Vitamins
 UnitPer {ml-col-1} mlPer {ml-col-2} ml
 
Minerals
 UnitPer {ml-col-1} mlPer {ml-col-2} ml
 

footnotes

Product details not available.